Moreover, studies reveal that CDCA5 serves an important part in the progression of a wide range of malignancies, including bladder cancer, prostate cancer, ovarian cancer and breast cancer, and participates in a variety of signaling pathways, such as the ERK signaling pathway and the PI3k/AKT/mTOR pathway 7-10. Here, CDCA5 is linked to ovarian carcinoma.